<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04443426</url>
  </required_header>
  <id_info>
    <org_study_id>KETO- CHF 1-10-72-362-18</org_study_id>
    <nct_id>NCT04443426</nct_id>
  </id_info>
  <brief_title>Modulation of Circulating Levels of the Ketone Body 3-hydroxybutyrate in Patients With Chronic Heart Failure: Cardiovascular Effects</brief_title>
  <acronym>KETO-KINETICS1</acronym>
  <official_title>Modulation of Circulating Levels of the Ketone Body 3-hydroxybutyrate in Patients With Chronic Heart Failure: Cardiovascular Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ketone body 3-hydroxybutyrate (3-OHB) is a naturally occurring energy substrate, and is&#xD;
      associated with increased life span and improved health. We have previously shown that&#xD;
      intravenous 3-OHB treatment increases myocardial blood flow &gt; 70% in healthy humans and data&#xD;
      from our group show that 3-OHB increases cardiac output by 40 % in patients with heart&#xD;
      failure.&#xD;
&#xD;
      In this study the investigators aim to investigate:&#xD;
&#xD;
        1. If this effect is reproducible with a commercially available oral ketone supplements&#xD;
&#xD;
        2. The safety of commercially available ketone supplements in heart failure patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart Failure (HF) is a major public health issue because the disease affects 1-2% of the&#xD;
      Western population and the lifetime risk of HF is 20%. HF is responsible for 1-2% of all&#xD;
      healthcare expenditures. Despite major improvements in the management and care of patients&#xD;
      with HF, the 1-year mortality in patients with HF is 13 % and &gt;50% of HF-patients is admitted&#xD;
      during a 2.5 year period. Furthermore patients with HF have markedly decreased physical&#xD;
      capacity and quality of life. Thus, there is a need for new treatment modalities in this&#xD;
      group of patients.&#xD;
&#xD;
      Ketone bodies are produced in the liver and are of vital importance in the human body for&#xD;
      energy generation in the heart and brain during fasting, exercise and severe illness. Ketosis&#xD;
      can be safely obtained using dietary supplements and can increase exercise capacity in&#xD;
      athletes. The most important ketone bodies are 3-hydroxybutyrate (3-OHB) and acetoacetate.&#xD;
      Recently, it was demonstrated that patients with severe HF have increased myocardial&#xD;
      utilization of the ketone body 3-hydroxybutyrate.&#xD;
&#xD;
      We have shown, using positron emission tomography, that ketone body infusion reduces&#xD;
      myocardial glucose uptake and increases myocardial blood flow in healthy subjects. Data from&#xD;
      another study conducted by our group show a 40% increase in cardiac output during infusion of&#xD;
      3-OHB.&#xD;
&#xD;
      Presently there are no data on the clinical cardiovascular and metabolic effects of long-term&#xD;
      oral ketone-supplementation in patients with chronic HF.&#xD;
&#xD;
      In this study the investigators will whether ketosis obtained by oral ketone supplements&#xD;
      affects hemodynamics and contractile function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 25, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac Output (L/min)</measure>
    <time_frame>5 hours</time_frame>
    <description>Right Heart Catherization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left Ventricle Ejection Fraction (%)</measure>
    <time_frame>5 Hours</time_frame>
    <description>Echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular filling pressure (mmHg)</measure>
    <time_frame>5 hours</time_frame>
    <description>Right Heart Catherization</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Heart Failure</condition>
  <condition>Ketosis</condition>
  <condition>Ketonemia</condition>
  <arm_group>
    <arm_group_label>Single dose oral 3-hydroxybutyrate monoester</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-over study in 8 patients receiving single-dose oral 3-hydroxybutyrate monoester, 3-OHB salt and placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose oral 3-hydroxybutyrate Salt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose oral placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>maltodextrin-based, isocaloric to ketone dosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral 3-hydroxybutyrate salts</intervention_name>
    <description>Comercially available 3-hydroxybutyrate salts with 36 grams of 3-OHB salts three times daily.</description>
    <arm_group_label>Single dose oral 3-hydroxybutyrate Salt</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Carbohydrate Placebo</intervention_name>
    <description>Comercially available carbohydrate sports drink. The placebo dose is isocaloric to the 3-hydroxy butyrate dose.</description>
    <arm_group_label>Single dose oral placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ketone Monoester</intervention_name>
    <description>Commercially available ketone monoester in a dosage isocaloric to 3-OHB salts.</description>
    <arm_group_label>Single dose oral 3-hydroxybutyrate monoester</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic Heart Failure;&#xD;
&#xD;
          -  NYHA class II-III&#xD;
&#xD;
          -  Left Ventricular Ejection Fraction &lt;40%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes or HbA1c &gt; 48 mmol/mol&#xD;
&#xD;
          -  Significant cardiac valve disease,&#xD;
&#xD;
          -  Severe stable angina pectoris&#xD;
&#xD;
          -  Severe comorbidity as judged by investigator,&#xD;
&#xD;
          -  Inability to give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristian H Christensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus Universitetshospital - Department of Cardiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 20, 2019</study_first_submitted>
  <study_first_submitted_qc>June 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2020</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Ketosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 15, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT04443426/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

